Sonic Healthcare Ltd (ASX: SHL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Sonic Healthcare Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $13.65 billion
P/E Ratio 27.32
Dividend Yield 3.60%
Shares Outstanding 477.74 million
Earnings per share 1.450
Dividend per share 1.05
Year To Date Return -7.79%
Earnings Yield 3.66%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Sonic Healthcare Ltd (ASX: SHL)
    Latest News

    Man holding out Australian dollar notes, symbolising dividends.
    Dividend Investing

    Seeking retirement income from ASX bank shares at 52-week highs? What I'd buy instead

    I’m banking on other stocks for my dividends.

    Read more »

    An older man wearing a helmet is set to ride his motorbike into the sunset, making the most of his retirement.
    Dividend Investing

    If I were 60 I'd buy these ASX shares for dividends

    These stocks could fit right into a 60-year-old’s portfolio.

    Read more »

    A man closesly watch a clock, indicating a delay or timing issue on an ASX share price movement
    Dividend Investing

    25 ASX 200 shares with ex-dividend dates next week

    There are 25 ASX 200 shares scheduled to go 'ex-div' next week.

    Read more »

    Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
    Broker Notes

    Morgans names 3 ASX stocks to buy following results

    Here are three stocks that Morgans is feeling bullish on this week.

    Read more »

    Shot of a young scientist using a laptop while conducting research in a laboratory.
    Healthcare Shares

    Sonic Healthcare shares hit 52-week low as analysts take a scalpel to targets

    Analysts have sharpened the knives after the latest blood-sucking half year at Sonic Healthcare.

    Read more »

    Shot of a young scientist looking stressed out while working on a computer in a lab.
    Earnings Results

    Sonic share price sinks after first-half profit crash

    The healthcare company's profits have almost halved.

    Read more »

    a mature aged couple dance together in their kitchen while they are preparing food in a joyful scene as the Breville share price rises on the back of a 25% profit surge
    Retirement

    Retirees: Here's how to boost your pension in 2024

    I’d look to these areas for additional income.

    Read more »

    A young office worker is surrounded by peers who are clapping and congratulating her.
    Opinions

    If I could buy only one ASX stock this February earnings season, it would be…

    Which ASX shares are impressing our writers in February?

    Read more »

    Man holding out $50 and $100 notes in his hands, symbolising ex dividend.
    Dividend Investing

    Here's how I think you can make a predictable 5% in passive income in 2024

    I’m backing these stocks to continue strong payouts.

    Read more »

    A couple sits in their lounge room with a large piggy bank on the coffee table. They smile while the male partner feeds some money into the slot while the female partner looks on with an iPad style device in her hands as though they are budgeting.
    Opinions

    Beginner investors: 5 top Aussie stocks I'd buy for 2024

    Confucious said, "Life is really simple, but we insist on making it complicated." Replace 'life' with 'investing' and it still…

    Read more »

    A smiling woman puts fuel into her car at a petrol pump.
    Dividend Investing

    The 3 best ASX dividend shares for 2024

    Experts at IML have declared this trio as the best income producers in Australia right now.

    Read more »

    cheap stocks represented by open brief case with golden light shining from it
    Healthcare Shares

    This 5%-yielding ASX 200 dividend giant looks like a hidden gem to me

    This is a very healthy opportunity in my opinion.

    Read more »

    Frequently Asked Questions

    Sonic Healthcare historically makes two partially or fully franked dividend payments to shareholders each year.

    Sonic Healthcare generally pays its shareholder dividends in March and September.

    Yes, Sonic Healthcare offers a dividend reinvestment plan (DRP) as an alternative to receiving cash dividends on its ordinary shares.

    Sonic Healthcare Ltd listed on the ASX on 30 April 1987.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    01 Mar 2024 $0.4300 0.00% Interim 21 Mar 2024
    06 Sep 2023 $0.6200 100.00% Final 21 Sep 2023
    07 Mar 2023 $0.4200 100.00% Interim 22 Mar 2023
    06 Sep 2022 $0.6000 100.00% Final 21 Sep 2022
    08 Mar 2022 $0.4000 100.00% Interim 23 Mar 2022
    07 Sep 2021 $0.5500 65.00% Final 22 Sep 2021
    09 Mar 2021 $0.3600 30.00% Interim 24 Mar 2021
    07 Sep 2020 $0.5100 30.00% Final 22 Sep 2020
    10 Mar 2020 $0.3400 30.00% Interim 25 Mar 2020
    10 Sep 2019 $0.5100 30.00% Final 25 Sep 2019
    08 Mar 2019 $0.3300 20.00% Interim 26 Mar 2019
    12 Sep 2018 $0.4900 30.00% Final 27 Sep 2018
    06 Mar 2018 $0.3200 20.00% Interim 10 Apr 2018
    08 Sep 2017 $0.0000 0.00% Final 11 Oct 2017
    07 Mar 2017 $0.3100 20.00% Interim 11 Apr 2017
    08 Sep 2016 $0.4400 30.00% Final 27 Sep 2016
    03 Mar 2016 $0.3000 30.00% Interim 06 Apr 2016
    05 Sep 2014 $0.4000 55.00% Final 23 Sep 2014
    03 Sep 2012 $0.2923 53.88% Final 09 Oct 2012
    04 Mar 2011 $0.1881 35.62% Interim 24 Mar 2011
    08 Sep 2010 $0.2818 43.47% Final 28 Sep 2010
    03 Mar 2010 $0.1932 43.48% Interim 25 Mar 2010
    08 Sep 2009 $0.2818 43.47% Final 28 Sep 2009
    05 Mar 2009 $0.1936 68.18% Interim 26 Mar 2009
    08 Sep 2008 $0.3200 100.00% Final 09 Oct 2008
    28 Feb 2006 $0.1500 100.00% Interim 20 Mar 2006
    31 Aug 2005 $0.2300 100.00% Final 19 Sep 2005
    26 Feb 2004 $0.1000 100.00% Interim 17 Mar 2004

    SHL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Sonic Healthcare Ltd

    Sonic Healthcare Limited (ASX: SHL) is a global healthcare provider. It is the largest private medical laboratory and pathology services operator in Australia, the United Kingdom, Germany, and Switzerland. It is the second-largest provider in Belgium and New Zealand and the third-largest in the United States.

    While pathology contributes the vast majority of the company's revenue, Sonic Healthcare is also a major provider of diagnostic imaging in Australia and is the largest medical centre operator in the country.

    The company typically earns the majority of its revenue from its European pathology segment, followed by its Australia-New Zealand pathology operations.  

    SHL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Mar 2024 $28.57 $-0.58 -1.99% 1,288,926 $29.25 $29.32 $28.57
    01 Mar 2024 $29.15 $-0.70 -2.35% 1,148,027 $29.11 $29.30 $28.72
    29 Feb 2024 $29.85 $0.55 1.88% 3,015,446 $29.38 $29.96 $29.35
    28 Feb 2024 $29.30 $0.00 0.00% 1,118,246 $29.20 $29.41 $28.92
    27 Feb 2024 $29.30 $-0.09 -0.31% 1,255,307 $29.08 $29.42 $29.04
    26 Feb 2024 $29.39 $0.09 0.31% 1,157,589 $29.36 $29.55 $29.21
    23 Feb 2024 $29.30 $0.33 1.14% 1,552,569 $28.94 $29.44 $28.81
    22 Feb 2024 $28.97 $-0.13 -0.45% 1,785,098 $28.92 $29.16 $28.69
    21 Feb 2024 $29.10 $-0.14 -0.48% 2,425,509 $28.59 $29.26 $28.11
    20 Feb 2024 $29.24 $-2.47 -7.79% 2,795,340 $30.44 $30.65 $28.96
    19 Feb 2024 $31.71 $-0.23 -0.72% 901,651 $32.07 $32.19 $31.58
    16 Feb 2024 $31.94 $-0.11 -0.34% 1,481,061 $32.31 $32.32 $31.80
    15 Feb 2024 $32.05 $-0.10 -0.31% 1,069,968 $32.25 $32.57 $31.82
    14 Feb 2024 $32.15 $-0.21 -0.65% 751,083 $31.76 $32.25 $31.71
    13 Feb 2024 $32.36 $0.25 0.78% 1,395,903 $32.05 $32.49 $32.00
    12 Feb 2024 $32.11 $0.31 0.97% 788,918 $31.85 $32.27 $31.74
    09 Feb 2024 $31.80 $0.36 1.15% 894,961 $31.64 $31.82 $31.51
    08 Feb 2024 $31.44 $0.17 0.54% 1,241,340 $31.48 $31.65 $31.25
    07 Feb 2024 $31.27 $-0.16 -0.51% 1,043,055 $31.40 $31.60 $31.14
    06 Feb 2024 $31.43 $-0.50 -1.57% 939,862 $31.82 $31.91 $31.43

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Dec 2023 Christine Bennett Buy 1,000 $29,000
    On-market trade.
    29 Nov 2023 Christopher Wilks Issued 25,051 $724,224
    Issue of securities. 81,738 Rights
    29 Nov 2023 Christopher Wilks Issued 131,395 $3,798,629
    Issue of options.
    29 Nov 2023 Colin Goldschmidt Issued 313,113 $9,052,096
    Issue of options.
    29 Nov 2023 Colin Goldschmidt Issued 59,696 $1,725,811
    Issue of securities. 198,552 Rights
    27 Nov 2023 Mark Compton Buy 1,000 $28,869
    On-market trade.
    22 Nov 2023 Suzanne Crowe Buy 1,200 $34,987
    On-market trade.
    20 Nov 2023 Kathryn (Kate) Spargo Buy 1,000 $29,439
    On-market trade.
    26 Sep 2023 Colin Goldschmidt Expiry 7,935 $241,858
    As advised by the company. 1,28,639 performance rights, forfeited
    26 Sep 2023 Colin Goldschmidt Expiry 60,086 $1,831,421
    Options expired.
    26 Sep 2023 Colin Goldschmidt Issued 10,217 $311,414
    Issue of securities. 1,38,856 performance rights
    26 Sep 2023 Christopher Wilks Issued 5,863 $178,704
    Issue of securities. 56,687 performance rights
    26 Sep 2023 Christopher Wilks Expiry 22,898 $697,931
    Options expired.
    26 Sep 2023 Christopher Wilks Expiry 3,024 $92,171
    As advised by the company. forfeited, 50,824 Rights
    25 Sep 2023 Colin Goldschmidt Transfer 31,495 $964,691
    As advised by the company. legally transferred
    25 Sep 2023 Colin Goldschmidt Transfer 31,495 $964,691
    As advised by the company. legally transferred
    25 Sep 2023 Christopher Wilks Transfer 16,412 $502,699
    As advised by the company. legally transferred
    25 Sep 2023 Christopher Wilks Transfer 16,412 $502,699
    As advised by the company. legally transferred
    07 Sep 2023 Christopher Wilks Sell 250,000 $7,786,450
    On-market trade.
    07 Sep 2023 Colin Goldschmidt Sell 462,372 $14,396,322
    On-market trade.
    06 Sep 2023 Colin Goldschmidt Exercise 462,372 $10,028,848
    Exercise of options.
    06 Sep 2023 Colin Goldschmidt Exercise 7,767 $243,417
    Conversion of securities. 1,36,574 Rights
    06 Sep 2023 Colin Goldschmidt Buy 7,767 $243,417
    Conversion of securities.
    06 Sep 2023 Colin Goldschmidt Issued 462,372 $10,028,848
    Exercise of options.
    06 Sep 2023 Christopher Wilks Exercise 205,415 $4,455,451
    Exercise of options.
    06 Sep 2023 Christopher Wilks Buy 4,048 $126,864
    Conversion of securities.
    06 Sep 2023 Christopher Wilks Exercise 4,048 $126,864
    Conversion of securities. 53,848 Rights
    06 Sep 2023 Christopher Wilks Issued 205,415 $4,455,451
    Exercise of options.
    23 Aug 2023 Katharine Giles Buy 1,000 $32,109
    On-market trade.
    21 Aug 2023 Christine Bennett Buy 1,000 $32,440
    On-market trade.
    18 Aug 2023 Mark Compton Buy 1,250 $41,212
    On-market trade.
    08 Mar 2023 Colin Goldschmidt Transfer 44,941 $1,506,422
    As advised by the company. 44,941 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt.
    08 Mar 2023 Colin Goldschmidt Issued 78,837 $2,642,616
    Conversion of securities.
    08 Mar 2023 Colin Goldschmidt Exercise 78,837 $2,642,616
    Conversion of securities. 1,44,341 performance rights
    08 Mar 2023 Colin Goldschmidt Transfer 44,941 $1,506,422
    As advised by the company. 44,941 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt.
    08 Mar 2023 Christopher Wilks Transfer 19,966 $669,260
    As advised by the company. 19,966 shares were withdrawn from SHEST and legal title transferred to Mr Wilks.
    08 Mar 2023 Christopher Wilks Transfer 19,966 $669,260
    As advised by the company. 19,966 shares were withdrawn from SHEST and legal title transferred to Mr Wilks.
    08 Mar 2023 Christopher Wilks Exercise 37,629 $1,261,324
    Conversion of securities. 57,896 Rights
    08 Mar 2023 Christopher Wilks Issued 37,629 $1,261,324
    Conversion of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Christopher David Wilks Chief Financial OfficerFinance Director Dec 1989
    Mr Wilks has a background in investment banking and was previously a partner in a private investment bank. Mr Wilks has held directorships in several public companies and is currently a Nonexecutive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996.
    Dr Colin Stephen Goldschmidt Chief Executive OfficerManaging Director Jan 1993
    Dr Goldschmidt Goldschmidt became CEO of Sonic in 1993 and has led Sonic's global expansion by committing the Company to a model of Medical Leadership, which incorporates operational and cultural attributes focused on care for staff and quality service to doctors and patients. He is a member of Sonic's Risk Management Committee and holds memberships with numerous industry, medical and laboratory associations.
    Mr Mark Raymond Compton Non-Executive DirectorNon-Executive Chairman Oct 2014
    Mr Compton has senior executive experience in healthcare services. He is currently Adjunct Professor in Management (Healthcare Leadership) at Macquarie University (Macquarie Business School), and Non-executive Chairman of not-for-profit organizations St Luke's Care and the Order of St John (St John Ambulance). His previous experience includes Chief Executive Officer of each of St Luke's Care, Immune Systems Therapeutics Limited and the Royal Flying Doctor Service of Australia.
    Mr Neville Mitchell Non-Executive Director Sep 2017
    Mr Mitchell has international healthcare and finance experience. He has also performed roles with a number of industry and government committees. Mr Mitchell is member of the Risk Management Committee.
    Mr Louis (Lou) James Panaccio Non-Executive Director Jun 2005
    Mr Panaccio has executive management experience in business and healthcare services. He is also a Non-executive Director of Unison Housing Limited, Non-executive Chairman of Azure Health Technology Limited, NeuralDx Limited and Magellan Stem Cells Pty Ltd (from August 2023). Mr Panaccio was the Chief Executive Officer and Executive Director of Melbourne Pathology (acquired by Sonic in 1999) for ten years to 2001, the Chief Executive Officer of Monash IVF until 2009, the Executive Chairman of Health Networks Australia until 2017 and a Non-executive Director of Haemokinesis Limited until October 2022. Mr Panaccio is a member of the Risk Management Committee.
    Professor Suzanne Crowe Non-Executive Director Apr 2020
    Professor Crowe was a Non-executive Director of St Vincent's Health Australia Ltd from January 2013 until October 2021. She retired from Burnet Institute as Associate Director in 2018 following a 30-year research career, having played a role in Burnet's development as a global research organization. Professor Crowe retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne in 2019 after 35 years of service. She has served as a Member of the Prime Minister's Science Engineering and Innovation Council (India/China Working Group), as Head of the World Health Organization (WHO) Regional Reference Laboratory for HIV Resistance Testing and as an HIV advisor to WHO for 25 years. Professor Crowe is Chair of the Risk Management Committee.
    Professor Christine Constance Bennett Non-Executive Director Sep 2022
    Prof Bennett has over 40 years of healthcare industry experience across the private, public and not-for-profit sectors. Her roles have involved providing clinical care, strategic planning, and senior operational management. She has an active commitment to and involvement in medical professional issues, social policy and medical research. She is an experienced non-executive director in publicly listed, private and social enterprises. She is currently a non-executive director of ASX-listed Regis Healthcare (since March 2018), and an outgoing non-executive director of Telstra Health Pty Ltd. In December 2021, Professor Bennett retired from The University of Notre Dame Australia where she was Deputy Vice Chancellor, Enterprise & Partnerships (in 2020 and 2021) and Dean, School of Medicine, Sydney for over ten years. Her professional experience has included being Group Executive and Chief Medical Officer for MBF and the Bupa Health and Care services, CEO and later Chair of Research Australia, Managing Director of Total Health Enterprise Ltd, Partner in Health and Life Sciences for KPMG Australia, CEO of Westmead Hospital and Community Health Services, General Manager for the Royal Hospital for Women and Head of Planning in NSW Health.
    Ms Kathryn (Kate) Dianne Spargo Non-Executive Director Jul 2010
    Ms Spargo has gained business experience as both a legal advisor, having worked in private practice and government, and as a director. Ms Spargo also holds non-executive director roles with CIMIC Group Limited (from September 2017), the Future Fuels Cooperative Research Centre, Geelong Football Club Limited and Jellis Craig. Ms Spargo was previously a Non-executive Director of Fletcher Building Limited and Xenith IP Group Limited.
    Dr Katharine Giles Non-Executive Director Sep 2022
    Dr Giles after initially practicing as a medical doctor, Dr Giles moved to commercial pursuits which combined science, medicine and health. Dr Giles is currently Managing Director and Chief Executive Officer of OncoRes Medical (since 2017), which specialises in biomedical innovation. Dr Giles is also a Venture Partner at Brandon Capital Partners (since 2012), a venture capital firm dedicated to developing and supporting Australian life sciences businesses. She was previously an Investment Manager with Stone Ridge Ventures, a fund manager specialising in seed-to-early-stage technology investment. Dr Giles has start-up experience in medical apps, diagnostics and fitness devices and has served on the boards of private healthcare-related technology companies. She is a member of the Curtin University Commercialisation Advisory Board.
    Mr Paul Joseph Alexander Company SecretaryDeputy Chief Financial Officer
    -
    Paul Joseph Alexander Company SecretaryDeputy Chief Financial Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 176,359,869 37.20%
    J P Morgan Nominees Australia Pty Limited 56,798,795 11.98%
    Citicorp Nominees Pty Limited 37,973,638 8.01%
    Jardvan Pty Ltd 15,109,474 3.19%
    BNP Paribas Noms Pty Ltd <DRP> 12,126,944 2.56%
    National Nominees Limited 8,143,486 1.72%
    BNP Paribas Nominees Pty Ltd <Agency Lending DRP A/C> 4,266,490 0.90%
    Argo Investments Limited 3,726,053 0.79%
    HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/C> 3,262,081 0.69%
    Australian Foundation Investment Company Limited 3,159,672 0.67%
    Netwealth Investments Limited <Wrap Services A/C> 3,011,026 0.64%
    BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <DRP A/C> 2,586,805 0.55%
    Blaise Mentha 2,000,000 0.41%
    Polly Pty Ltd <A/C Patterson Family> 1,817,416 0.38%
    HSBC Custody Nominees (Australia) Limited A/C 2 1,688,971 0.35%
    Citicorp Nominees Pty Limited <Colonial First State INV A/C> 1,598,882 0.34%
    Quintal Pty Ltd <Harken Family A/C> 1,587,908 0.33%
    IOOF Investment Services Limited <IPS Superfund A/C> 1,449,230 0.31%
    BNP Paribas Nominees Pty Ltd ACF Clearstream 1,384,017 0.29%
    HSBC Custody Nominees (Australia) Limited i 1,346,103 0.28%

    Profile

    since

    Note